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1. Introduction
G-protein coupled receptors (GPCRs) represent a class of therapeutic targets that have been widely
exploited for drug designs and development. Metabotropic glutamate receptors (mGluRs) belong
to Class C GPCRs and are predominantly involved in maintaining cellular homeostasis in the
central nervous system (CNS). The natural ligand of mGluRs, glutamate, interacts with recep‐
tor proteins leading to the activation of multiple signaling pathways. More recently, aberrant
glutamate signaling has been shown to play a role in the transformation and maintenance of
various cancer types, including melanoma. Glutamate secretion from these cells has been found
to stimulate regulatory pathways that control tumor growth, proliferation and survival. In
addition to synaptic transmissions, accumulating evidence suggesting other functional roles of
glutamatergic signaling in human malignancies has presented intriguing possibilities to make
mGluRs putative, novel targets for human cancer treatments. To this end, the aberrant expres‐
sion of metabotropic glutamate receptor 1 (mGluR1) was found as the driving force in inducing
melanomagenesis in transgenic mouse models. Since then, other subtypes of mGluRs have been
implicated in the pathogenesis of various cancer types such as malignant gliomas and medullo‐
blastomas. As such, increased efforts have been generated to elucidate the mechanisms by which
mGluRs confer oncogenic potentials. This chapter summarizes our current knowledge on the
participation of glutamate signaling in human cancers. Given that mGluRs are “druggable”
members of the GPCR superfamily and their oncogenic implications in cancer, further under‐
standing on anti-mGluR signaling pathways will be beneficial.
2. Glutamate and cancer
The amino acid L-glutamine is a precursor for peptide and protein synthesis, amino sugar
synthesis, and nucleotide synthesis. The amide of glutamate, glutamine, is the most abundant
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free amino acid with a concentration ranging from 500-900 µmol/L. In the majority of cell types,
the glutamine is rapidly converted to L-glutamate (we will refer to as glutamate), which is the
most abundant intracellular amino acid. Glutamate is a key component in cellular metabolism
contributing as a metabolic fuel for intermediates in energy producing pathways as well as an
important component in the body’s disposal of excess, or waste, nitrogen. Glutamate is a
principal excitatory neurotransmitter in the mammalian central nervous system where it is
involved in cognitive functions such as learning and memory. In an attempt to appease the
insatiable needs that transformed cell types require to sustain their energy expenditure and
biosynthetic requirements, tumor cells become major consumers of glutamine.
2.1. The role of glutamate in normal and cancer cells
The uncontrolled proliferation that represents the hallmark of neoplastic disease not only involves
deregulated cell proliferation but also requires adjustments in the energy metabolism that fuels
the cells growth. Normal eukaryotic cells process the conversion of glucose to pyruvate via the
metabolic pathway glycolysis in the cytosol, then to carbon dioxide in the mitochondria under
aerobic conditions through the process of cellular respiration. In oxygen deprived environ‐
ments, or hypoxic conditions, glycolysis is the preferred energy-generating pathway resulting in
a decrease in the amount of pyruvate available to the oxygen-consuming mitochondria. It has been
observed that even in the presence of physiological relevant levels of oxygen cancer cells have the
ability to reprogram their glucose metabolism allowing them to preferentially produce energy
via the glycolysis while maintaining the same level of respiration. This “anaerobic respiration” is
a process known as the Warburg Effect [1, 2, 3]. Although aerobic metabolism including oxida‐
tive phosphorylation is up to 15 times more efficient then anaerobic metabolism. However, the
metabolism of cancer cells occurs at an increased glycolytic rate up to 200 times than those of their
normal surrounding tissues. Cellular ATP production during such high rates of glycolytic flux
can easily exceed the ATP produced via oxidative phosphorylation. This high consumption of
glucose requires much more nicotinamide adenine (NAD+), which is consecutively regenerat‐
ed from the conversion of pyruvate to lactate by increased expression of lactate dehydrogenase
making glycolysis self-sufficient [8].
Glutamine serves as a major respiratory fuel of tumor cells and has been shown to be the
absolute requirement over glucose for many malignant cell types [4]. The importance of
glutamine in tumor cell metabolism is derived from its ability to satisfy the bioenergetic needs
of tumor cells as well as providing intermediates for macromolecular synthesis [5]. During
periods of rapid growth, the cellular demand for glutamine surpasses its supply. At this time
glutamine becomes essential and it is this reason that glutamine has been designated a
‘conditionally’ essential amino acid. Traditionally, the role of glutamine has been viewed to
function as storage for excess nitrogen and to traffic the nitrogen within, and between, various
organs. Metabolically, glutamine is used directly for reactions that require its γ-nitrogen, such
as nucleotide and hexosamine synthesis, or indirectly in reactions that utilize the α-nitrogen
(amino nitrogen) or its carbon skeleton for energy production and biosynthesis. These indirect
reactions are necessary to generate the metabolic intermediates required for cell growth, which
begin with the conversion of glutamine into glutamate. Being an abundant extracellular
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nutrient, glutamine is regularly converted into glutamate by phosphate-dependent glutami‐
nase (GLS), an enzyme found within the inner mitochondrial membrane that has been shown
to be overexpressed in both solid tumors and many tumor cell lines. In fact, the majority of
glutamine consumption in cancer cells is owed to mitochondrial GLS activity. Consequentially,
tumor cells have large intracellular pools of glutamate; through increased GLS activity, the
abundantly available amino acid glutamine is converted to less abundant glutamate, there-by
maintaining the cells’ increasing demand for glutamate metabolism. This is the initial step in
glutaminolysis, a series of biochemical reactions by which glutamine is degraded to glutamate,
aspartate, pyruvate, alanine, citrate and carbon dioxide thereby providing metabolic inter‐
mediates to feed and maintain cells in which aerobic respiration is the biosynthetic hub.
Glycolysis and glutaminolysis both share the capacity to generate NADPH and the secretion
of lactate (Figure 1). As mentioned previously, the initial step of glutaminolysis is the conver‐
sion of glutamine to glutamate, which is used, intracellularly, as a primary source of energy
for proliferating cells. This rate-limiting step of glutamine metabolism is the deamidation
reaction catalyzed by GLS. The products formed from this reaction, glutamate and ammonia,
are released into the cytosolic compartment of the inner mitochondrial membrane. Glutamate
is then further metabolized by conversion to α-ketoglutarate via either oxidative deamination
by glutamate dehydrogenase (GIDH) or alanine transaminase (ALT). The deamination
reaction is localized to the mitochondrial matrix compartment and yields both α-ketoglutarate
and ammonium. The transamination can occur in either the cytosolic and mitochondrial
compartments and produces α-ketoglutarate and alanine. Alpha-ketoglutarate is a key
intermediate in the citric acid cycle where it is metabolized to regenerate oxaloacetate (OAA)
through the production of malate. Mitochondrial metabolism of α-ketoglutarate into malate
also generates NADPH via oxidation into pyruvate in the cytosol [6]. The NADPH produced
is used by the rapidly metabolizing cell as a required electron donor in lipid synthesis and
nucleotide metabolism as well as in antioxidant defense by maintaining glutathione (GSH) in
its reduced state. GSH is the major thiol-containing endogenous antioxidant used by the cell
to protect against various sources of oxidative stress. Maintaining a supply of GSH is critical
for tumor cell survival since the elevated metabolic demand of the rapidly growing cell
generates DNA-damaging byproducts that lead to oxidative stress [7].
Proliferating cancer cells consume vast amounts of glucose but only a small portion of which
undergoes oxidative phosphorylation, even in the presence of sufficient oxygen [1]. It has been
established that these rapidly dividing cells prefer to utilize glycolysis, which yields less net
ATP molecules per glucose molecule. However, glycolysis can occur in hypoxic conditions
that are usually associated with the highly necrotic regions of rapidly proliferating tumor
masses. The end-product of glycolysis, pyruvate, can then enter the TCA cycle or is reduced
into lactate by lactate dehydrogenase A, which is then excreted in the interstitial fluid. Within
a tumor mass is a composition of genetically heterogeneous subpopulations of cancer cells that
differ in their energy production pathways. It is possible that these subpopulations have the
ability to function symbiotically within the tumor mass; one subpopulation of cells, consisting
of hypoxic, glucose-dependent cells, secretes lactate as waste while the other subpopulation,
located in a region that is more oxygenated, preferentially imports and utilizes the lactate
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Figure 1. Metabolic pathways including glycolysis and glutaminolysis. Glycolysis produces NADPH and 5-carbon ribose
via the pentose phosphate pathway (PPP) at glucose-6-phosphate (G-6-P) and detours toward lactate production
(aerobic glycolysis) at pyruvate. The carbons of glucose are further diverted into various synthetic pathways to gener‐
ate the precursors of hexosamines, amino acids and lipids. Mitochondria are fueled by the anapleurotic substrate, α-
ketoglutarate (α-KG), generated from glutamate. Depending on the oxygen supply, α-ketoglutarate metabolizes
through the tricarboxylic acid (TCA) cycle to malate and oxaloacetate (OAA) providing energy and a carbon resource
for lipids.
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produced by the first subpopulation to be used in the citric acid cycle [8, 9]. The idea of
“metabolic symbiosis“ that exists between hypoxic and aerobic cells in which lactate produced
by hypoxic cells and taken up by aerobic cells to be used in oxidative support the bioenergetic
needs of rapidly proliferating cancer cells within a solid tumor mass.
Cancer cells utilize TCA cycle intermediates to provide proliferating tumor cells with biosyn‐
thetic precursors (cataplerosis) as well as the production of ATP. The influx of metabolic
intermediates in an attempt to maintain the mitochondrial TCA cycle (anaplerosis) is due to,
in large part, glutaminolysis in which the first step is the conversion of glutamine to glutamate.
Beyond its role in intermediary metabolism and biomass production, glutamate is also
involved in influencing signal transduction pathways involved in promoting cellular prolif‐
eration, survival, and tumorigenesis. In the next section, we will review glutamate signaling
and its role in the process of cellular transformation.
3. Aberrant expression of G-protein coupled receptors in neoplastic
transformation
GPCRs are able to transduce extracellular signals into the cell via the activation of heterotri‐
meric G proteins. Malignant cells have been shown to appropriate the normal physiological
functions of GPCR and utilize them to upregulate cell proliferation, invade surrounding tissue,
increase blood supply, and evade cell death. In this section we will address the roles of GPCRs
in tumor progression and metastasis.
3.1. G-Protein coupled receptors
Guanine nucleotide binding-protein coupled receptors (GPCRs; G-protein coupled recep‐
tors) comprise a large and diverse family of seven-pass membrane helix proteins found in
most eukaryotic organisms. Members of the GPCR superfamily are diverse in their primary
structure. The principal function of GPCRs is to transmit information about the extracellu‐
lar  environment  via  recognition of  a  variety  of  ligands including peptide  and non-pep‐
tide hormones and neurotransmitters,  chemokines, prostanoids and proteinases, biogenic
amines, nucleosides, lipids, growth factors, odorant molecules and light to the interior of
the cell by interacting with G-proteins. G-proteins are heterotrimeric subunits, Gα, Gβ and
Gγ,  associated  with  the  inner  surface  of  the  plasma  membrane  where  they  function  as
dimers.  These  G-proteins  regulate  the  activity  of  small  molecules  that  act  as  second
messengers. Most of the human GPCRs can be found divided into five families based on
phylogenetic  criteria:  Glutamate,  Rhodopsin,  Adhesion,  Frizzled/Taste2  and  Secretin  (GRAFS
classification system) [10]. The total number of known and verified human GPCRs consists
of over 800 members. The Glutamate family consists of 22 human proteins categorized into
ionotropic  receptors  (iGluRs)  and  metabotropic  receptors  (mGluRs).  The  iGluR  family
consists  of  N-methyl-D-aspartate  receptors  (NMDAR,  α-amino-3-hydroxy-5-methyl-4-
isoazolepropionic acid receptors (AMPAR), and kainite receptors (KAR). The mGluR family
consists  of  eight  different  subtypes  (mGluR1-8)  [11].  The  mGluRs  are  coupled  to  G-
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proteins,  which  distinguishes  them  from  iGluRs,  which  contain  ligand-gated  ion-chan‐
nels. The mGluRs are key receptors in the modulation of excitatory synaptic transmission
in the central nervous system (CNS). The eight subtypes of mGluRs are further classified
into three groups (I,  II,  III)  based on sequence homology, signal transduction pathways,
and agonist selectivity. mGluR1 and 5 belonging to subgroup I; mGluR2 and 3 belonging
to subgroup II; and mGluRs 6, 7, and 8 belonging to subgroup III. The structures of mGluRs
are  composed of  a  heterotrimeric  extracellular  region,  a  seven-α  helical  transmembrane
region and a cytoplasmic region. The extracellular region is further divided into the ligand-
binding region (LBR) and the cysteine–rich region. The LBR has a sequence homologous
with the extracellular regions of both iGluR and the γ-amino butyric acid (GABA) receptor
[12, 13]. Table 1 lists the expression of mGluRs in non-neuronal cells.
Cell Type GPCR Reference
Melanocytes mGluR5 Frati et al.,2000
Kerotinocytes mGluR1, 2 Genever et al.,1999
Osteoclasts mGluR8 Morimoto et al.,2006
Pancreatic Islets/β cells mGluR5,8 Storto et al.,2006Tong et al.,2002
Hepatocytes mGluR5 Storto et al.,2000b
Myocytes mGluR1,2,3,5 Gill et al.,1999
Thymocytes mGluR1,2,3,5 Storto et al.,2000a
Embryonic Stem Cells mGluR4,5 Melchiorri et al.,2007
Table 1. Expression of mGluRs in select non-neuronal cells
3.2. GPCR signaling
The two principal signal transduction pathways involving GPCRs are the cAMP signaling
pathway and the phosphatidylinositol signaling pathway. Glutamate-stimulated activation
causes a conformational change in the extracellular domains, which catalyze the exchange of
a GTP for a GDP on the Gα subunit of the intracellularly coupled G-protein. This exchange
decreases the affinity of the Gα subunit for the Gβγ monomer at which time they either
dissociate or rearrange [14, 15]. The dissociated Gα and Gβγ subunits interact with and
modulate downstream signaling targets including adenylyl cyclases, phosphodiesterases,
phosphlipases, tyrosine kinases, and ion channels.[16, 17]. Group I mGluRs are coupled to
Gαq/Gα/11 G-proteins that, upon glutamate-mediated activation, result in stimulation of
phospholipase C beta (PLCβ). Activation of PLCβ causes hydrolytic cleavage of phosphatidy‐
linositol-4, 5-diphosphate (PIP2) resulting in the formation of diacyl glycerol (DAG) and
inositol 1, 4, 5-triphosphate (IP3). DAG remains bound to the membrane while IP3 is released
as a soluble structure into the cytosol. Release of these secondary messengers results in
increased calcium release from the endoplasmic reticulum and activation of protein kinase C
Recent Advances in the Biology, Therapy and Management of Melanoma168
(PKC) which phosphorylates other molecules, leading to altered cellular activity (Figure 2).
Group II and III mGluRs are coupled to Gαi/o G-proteins that, upon activation prevent the
formation of cyclic adenosine monophosphate (cAMP). Upon activation, group II mGluRs
couple to Gαi/o subunit. Gαi/o G-proteins can inhibit adenylyl cyclase activity. Activation of the
Gαi/o results in Gαi/o -mediated inhibition of adenylyl cyclase causing a reduced production of
cyclic adenosine monophosphate (cAMP).
Figure 2. Signal transduction pathways activated by mGluR1 stimulation. Activation of mGluR1 by its ligand, gluta‐
mate, results in the activation of signaling pathways that upregulate cell proliferation (MAPK) and promotes cell sur‐
vival (PI3K/AKT).
3.3. G-protein coupled receptors and cellular transformation
GPCRs comprise the largest known family of cell  surface receptors that mediate cellular
responses  to  a  diverse  array of  signaling molecules  including hormones,  neurotransmit‐
ters, and chemokines. In addition, potent mitogens such as thrombin, bombesin, lysophos‐
phatidic  acid (LPA),  gastrin-releasing peptide (GRP),  endothelin  and prostaglandins  can
stimulate  cell  proliferation  by  interacting  with  their  cognate  GPCR  in  various  homolo‐
gous cell types [18, 19, 20, 21, 22].
A fundamental trait of cancer cells involves their ability to sustain chronic proliferation. In
normal cells, the production and release of growth-promoting signals that allow entry and
progression through the cell cycle are tightly regulated. This regulation maintains cellular
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homeostasis promoting normal tissue structure and function and is controlled, in part, by
growth factors that bind cell-surface receptors, which usually transmit signals through
branched signaling pathways. By deregulating these signals, cancer cells are able to bypass
regulatory control allowing them to proliferate and grow unconditionally. Cancer cells can
acquire the ability to sustain proliferative signaling by producing these growth factors
themselves in which the cells respond through the expression of cognate receptors resulting
in autocrine proliferative stimulation. Alternatively, cancer cells may send signals to the
surrounding tissue in a paracrine-like manner causing them to release various growth factors
that promote growth of the cancer cells [23]. Activation of the surface receptors may also cause
the constitutive activation of downstream signaling pathways.
Overexpression of GPCRs is detected in various cancer types, contributing to tumor cell
growth once activated by circulating or locally produced ligands. The oncogenic potential of
G protein-coupled receptors was revealed with the discovery of the MAS receptor in 1986,
which provided a direct link between misregulated cell growth and GPCRs [24]. In contrast
to most oncogenes identified at that time, MAS did not harbor genetic mutations resulting in
its constitutive activation. Subsequent to its discovery, studies demonstrated that wild-type
GPCRs have the ability to become tumorigenic when exposed to an excess of locally produced
or circulating ligands and agonists while other GPCRs harboring mutations in key conserved
residues can have transforming activity even in the absence of their ligands [14, 16, 17, 25, 26,
27, 28]. It has also been found that the level of expression of GPCRs is not as imperative to
oncogenesis as is the receptor simply being expressed [28]. Since then, abnormal functioning
of GPCR pathways have been shown to be the cause of several human diseases, and a large
body of evidence links aberrant G-protein signaling to the development and progression of
certain cancers [17].
The oncogenic transformation of cell types by way of GPCRs occurs, in part, by the establish‐
ment of autocrine or paracrine feedback in which the cell releases the ligand which binds and
activates the receptor, maintaining its activation, as well as that of downstream effector
proteins leading to enhanced cell proliferation [29, 30]. mGluRs are members of GPCR with
glutamate as the natural ligand [31, 32]. Glutamate is the predominant excitatory neurotrans‐
mitter in the central nervous system and stimulates both ionotropic (ligand-gated ion channels)
and metabotropic (G-protein-coupled) glutamate receptors [33]. Previously, glutamate
signaling was believed to be exclusive to the central nervous system (CNS). It has since become
apparent that various peripheral, non-neuronal cells express different types of glutamate
receptors and these receptors are required for normal physiological function [34]. Studies have
demonstrated that not only are mGluRs involved in the normal maintenance and regulation
of physiological homeostasis, but they can also be involved in the progression of a variety of
human malignancies. Initially, because of prior implications of GPCR expression being
exclusive to the CNS, the first speculations of mGluRs in human cancers were in neuronal
tumors such as neuroblastoma, medulloblastoma and glioma [35, 36, 37]. It was found that
among these neuronal tumors that released excess amount of glutamate into the surrounding
microenvironment were growing at a much-increased rate compared to neuronal tumors that
were not secreting glutamate into their surroundings [38]. Subsequent studies revealed that
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inhibition of glutamate release correlated with a decrease in the proliferation of not only
neuroblastoma, rhabdomyosarcoma, brain astrocytoma, but also thyroid carcinoma, lung
carcinoma, colon adenocarcinoma and breast carcinoma while having no effect on the growth
rates of normal human fibroblast or bone marrow stromal cells [37].
Subclass Malignancy Reference
Group I
mGluR1
Melanoma
Chen et al 1996
Pollock et al.,2003
Ohtani et al 2008
Glioma
Breast
Aronica et al.,2003
Albasanz et al.,1997
Shinno et al.,1994
Speyer et al 2011
mGluR5
Osteosarcoma
Oral squamous cell carcinoma
Melanoma
Kalariti et al.,2007
Park et al.,2007
Choi et al 2011
Group II
mGluR2 Glioma D’Onofrio et al.,2003
mGluR3
Glioma
D’Onofrio et al.,2003,
Aronica et al , 2003
Arcella et al 2005
Melaonma Prickett et al 2011
Group III
mGluR4
Colorectal adenocarcinoma
Chang et al.,2005
Malignant Melanoma
Squamous cell carcinoma
Breast carcinoma
Medulloblastoma Lacovelli et al.,2006
mGluR6 -
mGluR7 -
mGluR8 Melanoma Prickett et al 2011
Table 2. Implications of mGluRs in human cancer
3.4. Ectopic expression of mGluR1
Our group has previously described an unknown mechanism of melanoma pathogenesis in
which the expression of an otherwise normal receptor, metabotropic glutamate receptor 1
(mGluR1)  in  an  unnatural  cellular  environment  (melanocytes)  is  able  to  upregulate  cell
proliferation and tumor development in vitro and in vivo. Chen and colleagues have establish‐
ed  a  transgenic  mouse  line  (TG-3)  that  spontaneously  develops  melanoma  with  100%
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penetrance that was constructed using a 2-kb genomic fragment, termed clone B, which was
previously shown to commit fibroblasts to undergo adipocyte differentiation [39, 40]. In an
attempt to establish an animal model of obesity, five founder animals were established using
clone B DNA: TG-1 through -5. Instead of the expected obese phenotype, one of the five
founders, TG-3, developed heavily pigmented lesions on the ears, around the eyes, and the
perianal  region at  approximately  eight  months  of  age.  Upon histological  analyses  these
pigmented lesions were identified as melanoma, Further examination shown these lesions
were metastatic as evident by detecting these pigmented lesions in distant organs includ‐
ing the lymph nodes, brain, bone, lung and muscle. Using physical mapping we identified a
single insertion of clone B in mouse chromosome 10, region A2, which is orthologous to
human chromosome 6q23-24. Further molecular mapping found a concurrent insertion of
clone B in a head-to-head, head-to-tail, tail-to-tail configuration and a deletion of approxi‐
mately  70-kb  of  the  host  sequences  located  in  intron  3  of  the  gene  encoding  mGluR1.
Assessment of mGluR1 at both the protein and mRNA levels revealed the expression of the
murine form of metabotropic glutamate receptor 1 only in the pigmented lesion but not
normal counterpart. These results suggested that ectopic expression of mGluR1 in melano‐
cytes might be the driving basis for melanoma development [41]. To verify this hypothesis,
we engineered a new transgenic mouse line [TG(Grm1)EPv] directing mGluR1 expression in
melanocytes under the control of a melanocyte-specific promoter, dopachrome tautomerase
(DCT). This new transgenic line displays a melanoma susceptibility phenotype and progres‐
sion very similar  to  the  TG-3 line  [42].  It  was concluded that  in  vivo,  aberrant  mGluR1
expression in melanocytes is sufficient to induce spontaneous melanoma development with
100% penetrance. Progeny that are heterozygous at the transgenic integration site develop
melanotic lesions as soon as 4 months post-natal while those homozygous at the integra‐
tion site develop lesions within 30 days after birth. Ohtani and co-workers confirmed our
observation with an inducible mGluR1 transgenic mouse model,  when the expression of
mGluR1 is conditionally activated in adult mice melanoma develops in these animals 100%
of the time [43]. The results that mGluR1 has a role in melanocytic neoplasia in the murine
system prompted our group to examine human melanoma for ectopic expression of the
human form of metabotropic glutamate receptor 1.  Examination of numerous melanoma
biopsies and cell lines demonstrated aberrant expression of the receptor in approximately
60% of the samples suggesting that mGluR1 may be involved in the oncogenesis of a subset
of human melanomas [41, 44]. These findings as well as those by others prompted our group
to explore the underlying mechanisms of mGluR1- mediated melanocytic transformation. In
a set of studies we confirmed that mGluR1 expression in melanocytes confers oncogenic
activities in vitro and is sufficient to cause malignant phenotype in vivo [45].
In both the murine and human melanoma cell lines, stimulation of mGluR1 by glutamate
results in similar if not identical formation of second messengers as described above for the
CNS. One of the second messengers, DAG, stimulates PKC. PKC plays a key role in a multitude
of cellular processes including apoptosis, malignant transformation, and metastasis [46] and
once it is activated it in turn can activate the MAPK and PI3K/AKT pathways [47, 48, 49, 50,
51]. It is well known that the RAS-RAF-MEK-ERK module of the MAPK signaling cascade
regulates cell proliferation and inhibits apoptosis. PI3K/AKT pathway activation is important
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for tumor cell survival, epithelial-mesenchymal transition (EMT), and angiogenesis [52]. In
addition, gain-of-function mutations causing constitutive activation in G-proteins also result
in the activation of downstream effector pathways leading to uncontrolled cell proliferation
and cell survival. This is often a consequence of specific amino acid substitutions in the GTP
binding region of the Gα subunit resulting in defective GTPase activity. The inability for GTP
to be cleaved to GDP allows constitutive activation of downstream effector molecules. Such
hypermorphic mutant G proteins in melanocytes were initially found to cause increased
dermal pigmentation in transgenic mice. It was later found that the two functionally related
G protein subunits, GNAQ and GNA11 encoding the stimulatory Gαq and Gα11 subunits of
heterotrimeric G-proteins respectively, are genetic hotspots for somatic mutations found in
early uveal melanoma pathogenesis [53]. These mutations were also detected in benign
intradermal melanocytic tumors as well as primary and metastatic ocular melanocytic tumors.
Therefore, activation of ectopically expressed metabotropic glutamate receptors in human cells
upregulate signaling pathways known to be important in the pathogenesis of human cancers
associated with increased growth and angiogenesis while interruption of such pathways
would result in a decrease in cell proliferation and survival.
The acquisition of tumor phenotypes is dependent not on one, but on successive alterations
in  the  genomes  of  neoplastic  cells.  Specific  genotypes  confer  selective  advantages  on
subclones  of  cells  enabling  them to  outgrow,  and eventually  dominate,  the  local  tissue
environment. This idea of multistage tumor progression can be viewed as a succession of
clonal expansion each triggered by chance acquisition of mutant genotypes transitioning a
cell  from  normal  through  pre-malignant  and  eventually  cancer.  One  stage  involved  in
malignant transformation of cell types is the ability of a cell to maintain its capacity to spread
and divide in the absence of a stable or inter surface to attach. In a study performed by Prickett
et  al,  exon  capture  sequencing  of  GPCRs  in  malignant  melanoma  specimens  identified
activating mutations within a region encoding for a member of the group II metabotropic
glutamate receptors, mGluR3. The mutations were found throughout the coding region and
affected the extracellular domains as well as the seven-transmembrane domain with two mini-
hotspots  located  proximal  to  the  transmembrane  domains.  Four  somatic  mutations
(mGluR3E767K, mGluR3S610L, mGluR3G561E, and mGluR3E870K) were found to selectively regu‐
late the phosphorylation of MEK1/2 kinase in vivo and induce micro metastasis in vivo. This
activation  resulted  in  the  increased  migration  and  anchorage  independence  growth  of
melanoma cells. These studies suggest the existence of a melanoma tumor type in which
activating mutations in mGluR3 can lead to hypersensitivity to agonist stimulation of the
MEK-MAPK pathway that bypasses the RAF/RAS genotypes.
In addition to melanoma, inappropriate glutamatergic signaling has been shown to be
sufficient in the dysregulating growth leading to the transformation of other cell types. The
ectopic expression of mGluR1 alone was able to induce the neoplastic transformation of
immortalized baby mouse epithelial cells (iBMK) in vitro and promote tumor cell proliferation
in vivo [54, 55]. The iBMK cell model was engineered to be immortal but not tumorigenic while
also retaining normal epithelial characteristics. It was shown that full-length wild-type
mGluR1 is tumorigenic when ectopically expressed in epithelial cells via stimulated MAPK
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and AKT signaling pathways. Additionally, studies performed by Speyer and colleagues
(2011) described mGluR1 expression in several triple-negative breast cancer cell lines (TNBC)
in which shRNA-mediated knockdown of mGluR1 expression as well as antagonists to the
receptor inhibited cell proliferation in TNBC lines. Malignancies involving other mGluRs
include mGluR4 first reported by Chang and colleagues that mGluR4 is overexpressed in more
than 40% of colorectal adenocarcinomas, malignant melanomas, laryngeal squamous cell
carcinomas, and breast carcinomas tested [56]. Among these cancers, there was a correlation
with mGluR4 overexpression and increased mortality rate in patients with colorectal carcino‐
ma. mGluR5 overexpression was found to induce melanoma in transgenic mice [57]. The
increased expression in mGluR5 in the mouse melanocytes was correlated with enhanced
levels of MAPK activation. These studies suggested that glutamatergic signaling plays a
significant role in the initiation, progression and maintenance in human malignancies.
4. mGluR1 expression is required to maintain transformed phenotype
In an attempt to maintain tumor phenotypes, cancer cells are able to limit or bypass apoptotic
cell response. In addition to manipulating cellular signals that control proliferation, oncogenic
mutations have a profound effect in the disruption of apoptosis. These disruptions cause
evasion of death response signals and have been shown to promote tumor initiation and
progression leading to multistage carcinogenesis [58, 59, 60]. Indeed, defects in apoptotic
pathways contribute to a number of human disease phenotypes from neurodegeneration to
malignancy. The phosphatidylinositol 3-kinase (PI3K), phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) have critical roles in the transmission of signals that control
multiple functions such as cell metabolism, proliferation, cell-cycle progression, and survival.
PI3Ks are divided into three types (type I, II and III) with type I being further divided into two
sub classes, class IA and IB. PI3Ks belonging to class IA are activated by receptor tyrosine
kinases (RTKs) and those classified in class IB are activated by GPCRs [61]. All type I PI3Ks
catalyze the conversion of the lipid phosphatidylinositol-4,5-bisphosphate (PIP2) to phospha‐
tidylinositol-3,4,5-triphosphate (PIP3) from activation of upstream receptors such as epider‐
mal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), platelet-derived
growth factor receptor (PDGFR) and insulin-like growth factor 1 receptor (IGF-1R), which
interact with the p85 regulatory subunit of PI3K [62, 63]. The Ras protein interacts by directly
activating p110 catalytic subunit of PI3K in a GTP-dependent manner. The activation of Ras is
regulated by the extracellular stimuli that interact with cell surface receptors of the tyrosine
kinase or seven transmembrane-spanning families [64]. Once activated Ras phosphorylates
MEK, the mitogen activated protein (MAP) kinase kinase, which in turn activates MAP kinase.
This cascade stimulates the MAP kinase pathway leading to phosphorylation of transcription
factor that promote cellular proliferation and survival.
4.1. PI3K/AKT/PTEN
The serine-threonine protein kinase,  AKT (also known as protein kinase B or  PKB) and
phosphoinositide-dependent kinase 1 (PDK1) are important downstream targets of PI3K. The
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main biological consequences of AKT activation are cell survival and increased cell growth.
AKT activation is known to involve in both mitogenic signaling and cell survival in a number
of human cancer types. Human AKT exists in three isoforms: AKT1, AKT2 and AKT3. PI3K
mediates  cleavage of  PIP2,which produce PIP3  at  the  inner  surface  of  the  plasma mem‐
brane.  PIP  which  acts  as  a  second messenger  to  recruit  AKT through interaction  of  its
pleckstrin homology (PH) domain, a domain conserved in signaling proteins that accumu‐
late at sites of PI3K activation. Phosphorylation of AKT is dependent on phosphorylation, in
part, by PDK1 [61, 65]. Activated AKT in turn mediates signaling through the phosphorylat‐
ing inactivation of a multitude of downstream targets involved in apoptosis, including the
phosphorylation of cyclic AMP response element--binding protein (CREB) as well as IκB
kinase (IKK), which further activates central regulators of cell death: nuclear factor –κB (NF-
κB) and p53. AKT-mediated induction of NF-κB occurs via activation of IκB which induces
degradation of the NF-κB inhibitor IκB leading to release of NF-κB from the cytoplasm and
translocation to the nucleus leading to the expression of survival genes such as IAP that
promotes survival by inhibiting downstream activation of caspase-9 and -3 [66, 67, 68, 69, 70].
AKT influences p53 activity through phosphorylation of the p53-binding protein, MDM2.
MDM2 regulates p53 function by targeting p53 for degradation by its E3 ubiquitin ligase.
AKT phosphorylation of MDM2 allows increased translocation of the proteasome to the
nucleus where it binds p53 resulting in its degradation [70, 71]. In addition, the oncological
significance of amplified AKT expression has been well documented in gastric carcinoma,
ovarian, pancreatic and breast tumors [72, 73, 74]. AKT phosphorylation of the apoptosis-
inducing protein, Bad, prevents binding of Bad to the antiapoptotic Bcl-2-type proteins, Bcl-2
and Bcl- xL.  Bad promotes cell  death by forming a non-functional hetero-dimer with the
survival  factor  Bcl-xL.  Upregulation  of  Bcl-xL  promotes  survival  by  regulating  coupled
respiration through supporting ATP/ADP exchange across the outer mitochondrial mem‐
brane [75]. Phosphorylation of Bad by AKT prevents heterodimerization with Bcl- xL restoring
its antiapoptotic function. In addition, it has also been implicated that PI3K-AKT has effects
on tumor-induced angiogenesis, mediated in part through hypoxia-induced factor-1α and
NF-κB induced expression of the proangiogenic growth factor, vascular endothelial growth
factor  (VEGF)  and  suppression  the  endogenous  antiangiogenic  molecule,  thrombospon‐
din-1 (TSP-1). VEGF and its receptor, VEGFR are major angiogenesis inducers associated with
tumor angiogenesis in numerous malignancies [76].
The PTEN tumor suppressor is a dual-specificity phosphatase, which has protein phosphatase
activity and lipid phosphatase activity that antagonizes the PI3K-AKT pathway and is found
to contain inactivating mutations in many human cancers. PTEN negatively regulates PIP3-
mediated signaling cascades by hydrolyzing the 3-phosphate to generate PIP2 making PTEN
critical in phosphatidylinositol homeostasis and regulating the proliferation and invasion of
many cancer cells [77].
AKT is an important regulator of cell growth and apoptosis that activate downstream from
PI3K and is inhibited by the actions of the tumor suppressor PTEN. The ability to promote cell
growth and suppress cell death suggests the PI3K/AKT /PTEN pathways are critical partici‐
pants in tumorigenesis. As previously stated, the ectopic expression of mGluR1 was detected
Glutamate Signaling in Human Cancers
http://dx.doi.org/10.5772/55174
175
in approximately 60% of human melanoma biopsies and cell lines examined while its expres‐
sion was not found in in normal skin or benign nevi [42, 44]. Stimulation of mGluR1 by an
agonist of the receptor, L-quisqualate, results in the activation of MAPK in mouse and human
melanoma cell lines independent of the presence of the most common NRAS/BRAF-activating
mutations [46]. Constitutively activated MAPK pathway is common in many human cancers
including melanoma, frequently due to mutations in the BRAF and RAS genes. In melanomas,
mutation rates for BRAF is ~60% and NRAS is ~20% [44, 78, 79]. Treatment of human melanoma
cells with a competitive antagonist of mGluR1, LY367385, which binds to the same catalytic
site as glutamate, showed dose-dependent inhibition of cell proliferation via suppression of
ERK activation [80]. In addition, a noncompetitive mGluR1 antagonist which binds to the
transmembrane domain of the receptor resulting in stabilization of inactive conformation,
BAY36-7620, suppressed cell growth and promoted apoptosis in cultured melanoma cells that
express mGluR1 [81]. Both LY367385 and BAY36-7620 were shown to result in a decrease in
the levels of the secondary messengers, IP3 and DAG, in these studies. Further investigation
of mGluR1 functionality and activity using dominant-negative mGluR1 (dn-mGluR1) mutant
yielded in an increase in the number of apoptotic cells as demonstrated by the increased
cleavage of poly-ADP ribose polymerase (PARP), a well-known marker of apoptosis. The dn-
mGluR1 mutants derived from small deletions or single base substitutions in the intracellular
loop 2 or 3, which have been shown previously to be essential in mGluR1 signaling [44, 46,
82]. These studies demonstrated that ablation of the functionality of mGluR1 in melanoma
cells, we were able to reduce cell proliferation and induce cell death in vitro without affecting
normal cell types [44].
5. Inhibition of mGluR1
Targeting strategies for cancer therapy differ from chemotherapy and radiotherapy in their
potential to provide tumor specificity. Preclinical studies have demonstrated that inhibition
of glutamatergic signaling results in decreased tumor cell growth and increased cell death.
Identifying key upstream molecular targets that lead to the activation of proliferation and
survival pathways is important in cancer drug discovery. Gene-targeting techniques that
selectively inactivate gene expression assist in the validation of novel proteins involved in
disease pathogenesis.
5.1. Suppression of mGluR1 by siRNA
Gene silencing by short-interfering RNAs (siRNAs) has been used to investigate their roles in
different cell types and in various organisms. However, constitutive suppression the expres‐
sion of a gene could have deleterious consequences therefore, inducible silencing RNA
approaches could be useful by relying on small molecules that act as inducers to modify
synthetic transcription factors thereby regulating the expression of a target gene [83-87]. The
tetracycline operon based tetracycline inducible system and the non-mammalian steroid based
ecdysone inducible system are two complementary approaches we have used. Previous
attempts to inhibit mGluR1 expression in human melanoma cells using constitutively ex‐
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pressed mGluR1 specific siRNAs resulted in the cells exhibiting a dormancy-like state prior to
dying. Employing the inducible knock-down of mGluR1 was shown to result in suppression
of MAPK as evident by a decrease in the phosphorylated form of ERK as well as inhibition of
the PI3/AKT cell survival pathway seen by the reduced form of activated AKT [84]. Our
previous studies on mouse melanoma cells as well as mouse melanocytic clones that stably
expressed mGluR1 showed elevated levels of glutamate were released into their surroundings
compared to normal mouse melanocytes or vector controls [85]. This finding correlated with
earlier works in rats in which suppression of glutamate uptake coupled with stimulation of
group I mGluRs results in an increase in the accumulation of extracellular glutamate. It was
implicated that these mGluRs may work systematically with cystine-glutamate exchangers to
regulate extracellular glutamate concentrations [86, 87]. From this discovery, Chen and co-
workers hypothesized that instead of inhibiting mGluR1 directly, if they were able to interrupt
the autocrine/paracrine activity by limiting the amount of free ligand this would result in a
similar decrease in cell proliferation/survival.
5.2. Suppression of mGluR1 using an inhibitor of glutamate release
Glutamate is a major excitatory neurotransmitter in the CNS. The over activation of neu‐
rons  by  excessive  glutamate  stimulation  is  excitotoxic,  resulting  in  neuronal  death  [88].
Interestingly, the brain is one of the most common sites of metastatic melanoma. It is possible
the excessive glutamate found in the brain promotes tumor growth while inducing excitotox‐
icity to the surrounding neuronal tissue. Because of this, Chen and co-workers took advant‐
age of using an inhibitor of glutamate release, riluzole, a Food and Drug Administration
(FDA)-approved drug for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s
disease). ALS is a degenerative motor neuron disease of the upper and lower motor neu‐
rons that progressively causes weakness, muscle atrophy and fasciculation. Riluzole is known
to inhibit the release of glutamate from the presynapse resulting in a decrease of the molecule
in the synaptic cleft resulting in a decrease in excitotoxicity caused by the neurotransmitter.
This leads to a decreased progression of ALS [89]. Riluzole treated melanoma cells showed
a reduction in the levels of glutamate in the surroundings in vitro, which correlated with a
decrease in cell growth in vivo when compared to normal cells exposed to the drug. Addition‐
ally, melanoma cells treated with relatively low concentrations of riluzole were shown to
undergo apoptosis by an increase in the levels of the cleaved form of PARP after riluzole
treatment.  The  therapeutic  potential  of  riluzole  was  validated  in  vivo  using  a  human
melanoma cell xenograft model where animals were treated with a human equivalent of the
maximally allowed daily amount of riluzole per body weight per day via p.o. gavage for 18
days. The use of riluzole as a putative antagonist of mGluR1 to inhibit glutamate signaling
resulted in a reduction in tumor volume in treated animals vs. control. These results were
translated to the clinic.
5.3. Translational study in patients
Clinical trials involving new compounds are classified into four phases: Phase 0, I, II and
III. Phase 0 is the designation for exploratory, first-in-human trials conducted with the U.S.
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FDA’s guidelines on Exploratory Investigational New Drug Studies (IND). Phase 0 trials
are  designed  to  speed-up  the  development  of  promising  drugs  or  imaging  agents  by
establishing very early on whether the drug or agent behaves in human subjects as was
anticipated from preclinical  studies.  Based on results from previous findings in preclini‐
cal  studies using riluzole,  a phase 0 trial  using the compound in patients with stage III
and  IV  melanoma  was  performed  to  see  if  in  itds  presence  the  target,  glutamatergic
signaling, is reduced. The trial resulted in a significant short-term response rate of 34% of
patients. Tumors from patients that displayed shrinkage of tumors showed an inhibition
of signaling through both the MAPK and PI3K/AKT pathways, reflecting results that were
previously observed in preclinical  studies  [44,  90].  Positron Emission tomography (PET)
documented  complete  resolve  of  multiple  nodal  and  cutaneous  metastases  in  several
patients.  One  patient  having  six  different  tumors  measured  by  PET/CT  demonstrated
shrinkage of the lesions by 10% to 20%. Out of eleven patients that completed the study,
only two had shown progression of the disease after treatment [90].  The tumor samples
were a composed of patients harboring both V600E BRAF as well as Q61K NRAS muta‐
tions.  In  addition  all  the  patients  admitted  into  the  trial  expressed  mGluR1,  although
mGluR1 expression status was not a requirement for entry.  It  is  possible that,  from this
observation, that more advanced tumors, those found in stage III and IV metastases, have
a higher  frequency of  mGluR1 expression and that  ectopic  mGluR1 occurs  and is  more
frequent in more progressed stages of the disease.
6. Conclusion
Melanoma is a genetically diverse disease owing to the dysfunction of multiple regulato‐
ry pathways. As such, it is important to test the therapeutic potential of agents that reflect
the genetic diversity of this disease. In addition to ectopic expression of mGluR1, muta‐
tions in BRAF have been identified in more than 60% of melanomas, most of these due to
the substitution of a single amino acid at residue 600 in the B-RAF kinase domain resulting
in constitutive activation of the RAF/MAP/ERK kinase signaling pathway [91]. Melanoma
cells  with  aberrant  glutamate  receptor  signaling also  exhibit  hyperactive  PI3K/AKT and
MEK/MAPK  pathways  [44,  92,  93].  Additionally,  a  recent  examination  of  a  publicly
available  gene  expression  data  bank  identified  a  variety  of  GPCRs  that  are  over-ex‐
pressed  in  diverse  types  of  cancer  tissues  [94].  These  findings  illustrate  the  role  that
glutamate receptors and transporters play in the cellular signaling somatic cell types. The
molecular  physiology  of  GPCRs  allow  them  to  be  regulated  by  many  agonists  and
antagonists and are the target, directly and indirectly, of approximately 50% of pharmaceut‐
ical agents used to treat various human diseases. GPCRs have been shown to have a role
in both normal and aberrant mitogenic signaling in functions that regulate cell migration
in tumor metastasis and angiogenesis as well as key molecular events implicated in cancer
progression  and  invasion.  Based  on  these  findings,  it  is  perhaps  not  surprising  that
interruption of the glutamatergic signaling pathway by targeting GPCRs in cancers could
result in more effective the treatment of this devastating disease.
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